Bilessglu (chiglitazar) / Chipscreen - LARVOL DELTA

The effects of chiglitazar and metformin on insulin resistance in women with a normal BMI and polycystic ovary syndrome: a randomized controlled study. (PubMed, BMC Endocr Disord) - P2/3 | "In normal-weight PCOS patients, chiglitazar is similar to MET with regard to improving menstrual frequency and total testosterone (TT) and LH levels. Compared with MET, chiglitazar significantly improves fasting insulin levels, insulin and blood glucose levels at 120 min of the OGIRT and advances the insulin peak."

Journal • Diabetes • Metabolic Disorders • Obesity • Polycystic Ovary Syndrome • Type 2 Diabetes Mellitus • PRL

Resensitizing the Imatinib-Resistant Chronic Myeloid Leukemia through Reshaping the Glucose Mtabolism By Insulin Sensitizer (ASH 2024) - "Chiglitazar (Chi), a novel Insulin Sensitizer, reduced the glucose metabolism in stem-like cell of Acute Myeloid Leumia (AML) according to our previous study. Finally, in vivo data confirmed the anti-leukemic effect of Chi and IM combination regimen in CDX (cell derived xnograft) models. Thus, we concluded that combining Chi and IM serves as a potential thrapeutic regimen in CML clinical management."

Acute Myelogenous Leukemia • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Oncology • PKM • PPARG

Peroxisome proliferator-activated receptors-mediated diabetic wound healing regulates endothelial cells' mitochondrial function via sonic hedgehog signaling. (PubMed, Burns Trauma) - "In vivo, diabetic mice treated with PPAR agonists (chiglitazar) underwent wound healing assessment, including collagen deposition and angiogenesis...Activation of the PPARs/SHH-mitochondrial axis significantly enhances endothelial cell metabolism and angiogenesis. This study provides insights into the molecular mechanisms of diabetic wound healing and supports the clinical potential of PPAR agonists for DFU treatment."

Journal • Diabetes • Metabolic Disorders • CD31 • PECAM1 • PPARA • SHH

Therapeutic Activation of PPARα Inhibits Transformed Follicular Lymphoma Tumorigenesis via the FOXM1 Signaling Pathway. (PubMed, Int J Biol Sci) - "Concurrently, knockdown of FOXM1 enhances the sensitivity of t-FL cells to chiglitazar, and overexpression of FOXM1 partially rescued the inhibitory effect of chiglitazar on t-FL cells, highlighting the involvement of the PPARα-FOXM1 axis in the antitumor effects of chiglitazar. These promising preclinical results support further clinical evaluation of chiglitazar as a potential therapeutic option for t-FL patients, providing a novel and effective treatment approach for this aggressive subtype of FL."

Journal • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Oncology • FOXM1 • HIF1A • PPARA

A comparative analysis of cost-utility: Chiglitazar vs. sitagliptin in patients with type 2 diabetes in China. (PubMed, J Diabetes Complications) - "Based on cost-utility analysis within the Chinese healthcare context, chiglitazar demonstrates significantly better long-term health outcomes and cost-effectiveness relative to sitagliptin for T2DM management."

HEOR • Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Efficacy and safety of chiglitazar add-on to metformin in type 2 diabetes mellitus (RECAM study). (PubMed, Diabetes Obes Metab) - P3 | "Chiglitazar combined with metformin significantly improves glycaemic control and lipid metabolism in Chinese patients with T2DM who are inadequately managed with metformin and have a favourable safety profile."

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Baseline Plasma GPX3 Level Predicts Efficacy of Insulin-Sensitization Drug Chiglitazar in Type 2 Diabetes. (PubMed, Phenomics) - No abstract available

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Efficacy and safety of insulin sensitisers for treating type 2 diabetes: a network meta-analysis. (PubMed, Eur J Clin Pharmacol) - "Compared with placebo, all four drugs were safe and effective in the treatment of T2DM. High-dose TZDs may be more effective than mitiglinide and sitagliptin. However, 45 mg of pioglitazone was associated with a higher incidence of adverse events, warranting close monitoring of its safety profile."

Journal • Retrospective data • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Chiglitazar in MASLD with hypertriglyceridemia and insulin resistance: A phase II, randomized, double-blind, placebo-controlled study. (PubMed, Hepatology) - "Chiglitazar significantly reduced liver fat content in MASLD with hypertriglyceridemia and insulin resistance, with a dose-dependent effect and favorable safety profile."

Clinical • Journal • P2 data • Dyslipidemia • Fibrosis • Hepatology • Hypertriglyceridemia • Immunology • Liver Cirrhosis • Liver Failure • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Metabolic Dysfunction-Associated Steatotic Liver Disease

The impact of chiglitazar, a pan-PPAR agonist, on metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes: a real-world study. (PubMed, Diabetes Metab) - "Chiglitazar administration is associated with a significant reduction in CAP values in T2D patients with MASLD, suggesting its potential as a dual therapeutic approach for both conditions."

Journal • Real-world evidence • Diabetes • Fibrosis • Hepatology • Immunology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Type 2 Diabetes Mellitus

Clinical observation of pioglitazone or sitaglipta sodium combined with metformin in the treatment of newly diagnosed type 2 diabetes with fatty liver (ChiCTR) - P4 | N=80 | Not yet recruiting | Sponsor: The First Affiliated Hospital of Chengdu Medical College; Chengdu Medical University First Affiliated Hospital"

New P4 trial • Diabetes • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Type 2 Diabetes Mellitus

Integrated Metabolomics and Lipidomics Analysis Reveals the Mechanism Behind the Action of Chiglitazar on the Protection Against Sepsis-Induced Acute Lung Injury. (PubMed, Metabolites) - "Co-treatment with EX-527 in LPS-stimulated BEAS-2B cells and CLP rats inhibited the effects of chiglitazar on the aforementioned signaling pathways and worsened the protective effects of chiglitazar on lung injury, respectively. Chiglitazar alleviates SALI by restoring NAD+ and TG synthesis, highlighting the balancing of metabolism as a promising therapeutic strategy in the management of SALI."

Journal • Acute Lung Injury • Infectious Disease • Metabolic Disorders • Respiratory Diseases • Septic Shock • PPARA

Administration of chiglitazar reverses chronic stress-induced depressive-like symptoms in mice via activation of hippocampal PPARα and BDNF. (PubMed, Front Pharmacol) - "Peroxisome proliferator-activated receptor α (PPARα) has been demonstrated to play a role in the pathophysiology of depression, and several PPARα agonists including WY14643, fenofibrate, and gemfibrozil, have all been reported to possess antidepressant-like efficacy in rodents. Genetic knockdown of hippocampal PPARα and BDNF also abolished the antidepressant-like actions of chiglitazar in mice. In summary, administration of chiglitazar reverses chronic stress-induced depressive-like symptoms in mice via activation of hippocampal PPARα and BDNF."

Journal • Preclinical • CNS Disorders • Depression • Gene Therapies • Psychiatry • BDNF • PPARA

Clinical study of insulin resistance and hormonal improvement by chiglitazar in polycystic ovary syndrome (ChiCTR) - P4 | N=112 | Not yet recruiting | Sponsor: The Second Affiliated Hospital of Chongqing Medical University; The Second Affiliated Hospital of Chongqing Medical University

New P4 trial • Polycystic Ovary Syndrome

A multicenter, prospective, single-arm clinical study on the treatment of refractory/relapsed acute myeloid leukemia R/RAML with Chiglitazar Sodium combined with Venetoclax and Azacitidine(CVA) (ChiCTR) - P2 | N=30 | Not yet recruiting | Sponsor: The First Affiliated Hospital of Xiamen University; The First Affiliated Hospital of Xiamen University

New P2 trial • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology

A multicenter, randomized controlled study of silymarin and chiglitazar sodium in patients with T2DM and MASLD (ChiCTR) - P4 | N=250 | Not yet recruiting | Sponsor: Zhongda Hospital of Southeast University; Zhongda Hospital of Southeast University

New P4 trial • Diabetes • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Type 2 Diabetes Mellitus

Pan-PPAR Agonist Chiglitazar for the Treatment of High-Risk Metabolic Dysfunction-Associated Steatohepatitis Coexisting with Type 2 Diabetes: A Randomized, Double-Blind, Phase 2 Trial (APASL 2025) - P4 | "Chiglitazar demonstrated a favorable efficacy and safety profile in the treatment of T2DM patients at high risk of MASH. These findings support its further evaluation in a phase 3 trial. Table and Figure:Figure 1.Primary endpoints of the study Figure 2.Changes in clinical characteristics from baseline to week 24"

Clinical • P2 data • Diabetes • Fibrosis • Hepatitis C • Hepatology • Immunology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Type 2 Diabetes Mellitus

Comparing Efficacy of Chiglitazar, Pioglitazone, and Semaglutide in Type 2 Diabetes: A Retrospective Study. (PubMed, Diabetes Ther) - "Chiglitazar is particularly effective for participants with pronounced dawn phenomenon, semaglutide excels in lipid metabolism improvement and kidney protection, while pioglitazone remains effective for insulin resistance and glycemic control. These findings provide evidence-based guidance for individualized T2D management."

Journal • Retrospective data • Cardiovascular • Diabetes • Dyslipidemia • Inflammation • Metabolic Disorders • Renal Disease • Type 2 Diabetes Mellitus

Evaluation of the Regulatory Effect of the Pan-PPAR Agonist Chiglitazar on the Dawn Phenomenon. (PubMed, Diabetes Ther) - "Chiglitazar effectively reduces DP intensity and improves glycemic control, independent of its effects on lipid metabolism. These findings suggest a potential link between chiglitazar's mechanism and circadian rhythm regulation, possibly through the modulation of REV-ERB nuclear receptors. Further research is needed to confirm this hypothesis and evaluate the long-term clinical benefits of chiglitazar in diabetes management."

Journal • Diabetes • Metabolic Disorders

The Efficacy and Safety of Chiglitazar in Patients with MAFLD-related Cirrhosis (clinicaltrials.gov) - P=N/A | N=195 | Not yet recruiting | Sponsor: Beijing Friendship Hospital

New trial • Fibrosis • Gastroenterology • Hepatology • Immunology • Liver Cirrhosis • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease

Therapeutic effects of chiglitazar combined with Rosa roxburghii Tratt. in inpatients with antipsychotic-induced metabolic syndrome. (PubMed, Pak J Pharm Sci) - "Importantly, the Chiglitazar + RRT group exhibited a significantly lower PANSS score at 12 weeks compared to baseline, indicating improved psychiatric symptoms. Chiglitazar combined with RRT effectively improves metabolic parameters, reduces inflammation and ameliorates psychiatric symptoms in inpatients with antipsychotic-induced MetS."

Biomarker • Clinical • Journal • CNS Disorders • Inflammation • Mental Retardation • Metabolic Disorders • Psychiatry • IL6 • TNFA

Chiglitazar/Metformin in Non-obese Women With PCOS (clinicaltrials.gov) - P2/3 | N=55 | Completed | Sponsor: Shengjing Hospital | Enrolling by invitation ➔ Completed | N=40 ➔ 55 | Trial completion date: May 2026 ➔ Nov 2024 | Trial primary completion date: Apr 2026 ➔ Oct 2024

Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Obesity • Polycystic Ovary Syndrome

Chiglitazar Sodium Combined With Venetoclax and Azacitidine (CVA) for the Treatment of R/R AML (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: The First Affiliated Hospital of Xiamen University

New P1 trial • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

Chiglitazar diminishes the warburg effect through PPARγ/mTOR/PKM2 and increases the sensitivity of imatinib in chronic myeloid leukemia. (PubMed, Exp Hematol Oncol) - "Our results demonstrated the potential of Chi to overcome IM resistance in vitro and in vivo. By inhibiting the Warburg effect through the PPARγ/mTOR/PKM2 pathway, Chi resensitizes CML cells towards imatinib treatment. Combining IM with Chi is an alternative therapeutic option for CML management, especially for IM-resistant CML patients."

Journal • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Oncology • Transplantation • PKM • PPARG

Chiglitazar ameliorates dehydroepiandrosterone-induced polycystic ovary syndrome in rats. (PubMed, J Ovarian Res) - "Chiglitazar significantly improved ovulation in rats with PCOS and may be a potential novel therapeutic strategy for PCOS."

Journal • Preclinical • Atherosclerosis • Cardiovascular • Dyslipidemia • Metabolic Disorders • Polycystic Ovary Syndrome • SLC2A4